Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Carmustine + Cytarabine + Etoposide + Melphalan + Yttrium Y 90 Basiliximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carmustine||Becenun||BCNU||Chemotherapy - Alkylating 16||Becenun (carmustine) is an antineoplastic alkylating agent, which cross-links DNA and disrupts the cell-cycle (NCI Drug Dictionary).|
|Cytarabine||Cytosar-U||Ara-C||Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309).|
|Etoposide||Vepesid||EPEG|Eposin|VP-16|VP-16-213||TOPO2 inhibitor 5||Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).|
|Melphalan||Alkeran||Chemotherapy - Alkylating 16||Alkeran (melphalan) is an antineoplastic alkylating agent, which cross-links DNA and induces cell toxicity and is FDA approved for multiple myeloma and epithelial ovarian carcinoma (FDA.gov).|
|Yttrium Y 90 Basiliximab||90Y basiliximab||Yttrium Y 90 Basiliximab consists of an anti-IL-2 receptor antibody (basiliximab) conjugated to radioactive yttrium Y 90, which binds to IL-2R and prevents IL-2 binding, as well as delivering cytotoxic radiation to IL-2R expressing cells, thereby potentially decreasing T-cell activation and immune response (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02342782||Phase I||Carmustine + Cytarabine + Etoposide + Melphalan + Yttrium Y 90 Basiliximab||Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma||Active, not recruiting||USA||0|